Home Blog Page 2

HOXB13 Genetic Test: Hereditary Prostate Cancer Risk and Family History

Learn what a HOXB13 genetic test means, how the G84E variant affects hereditary prostate cancer risk, and what positive, negative, and family results can imply.

A HOXB13 genetic test looks for inherited variants in the HOXB13 gene that can raise a person’s lifetime risk of prostate cancer. The best-studied...

Metastatic Prostate Cancer Biomarker Panel: PSA, PSMA, HRR Genes, MSI, and Tumor Profile

Learn how PSA, PSMA PET, HRR genes, MSI/dMMR, germline testing, tumor sequencing, and ctDNA guide treatment decisions in metastatic prostate cancer.

A metastatic prostate cancer biomarker panel is not one single laboratory test. It is a coordinated set of blood tests, molecular tests, pathology findings,...

Oncotype DX Genomic Prostate Score Test: Prostate Cancer Risk and Genomic Score

Learn how the Oncotype DX Genomic Prostate Score measures tumor gene expression, what a 0–100 GPS result means, and how it can guide prostate cancer care.

The Oncotype DX Genomic Prostate Score test, now commonly called the Genomic Prostate Score (GPS), is a tissue-based gene-expression test used after prostate cancer...

PCA3 Urine Test: Prostate Cancer Risk, Repeat Biopsy, PSA Follow-Up, and Meaning

Learn what a PCA3 urine test measures, how scores such as 25 are interpreted, and how PCA3 fits with repeat biopsy, PSA, MRI, and newer biomarkers.

The PCA3 urine test measures prostate cancer gene 3 RNA shed from prostate cells into urine after the prostate is stimulated during a digital...

Prolaris Test: Prostate Cancer Cell Cycle Score and Disease Aggressiveness

Learn how the Prolaris test measures 31 cell-cycle genes, what higher or lower scores mean, and how results can refine prostate cancer surveillance and treatment.

The Prolaris test is a tissue-based prostate cancer prognostic test that measures the activity of 31 cell-cycle progression genes to estimate how quickly the...

ProMark Test: Prostate Cancer Protein Biomarker Score and Prognosis

Learn how the ProMark prostate cancer test measures eight protein biomarkers, what a 1–100 score means, and how results can refine prognosis and surveillance decisions.

The ProMark test is a protein-based prognostic assay performed on prostate biopsy tissue after cancer has been diagnosed. It measures eight proteins linked to...

Prostate Cancer Biomarker Panel: PSA, Free PSA, PHI, 4Kscore, PCA3, and Risk Assessment

Prostate cancer biomarker panels combine PSA, free PSA, PHI, 4Kscore, PCA3, MRI, and clinical risk factors to guide biopsy decisions and assess significant cancer risk.

A prostate cancer biomarker panel is not one universal laboratory panel. In practice, clinicians combine selected blood or urine biomarkers with age, prostate exam...

Prostate Cancer HRR Gene Panel: BRCA, ATM, CHEK2, PALB2, and DNA Repair Defects

Prostate cancer HRR gene panels test BRCA1, BRCA2, ATM, CHEK2, PALB2, and related DNA-repair genes to guide hereditary risk assessment and precision treatment decisions.

A prostate cancer HRR gene panel looks for alterations in genes involved in homologous recombination repair, a major pathway cells use to repair double-strand...

Prostate Health Index (PHI) Test: p2PSA, Free PSA, Total PSA, and Cancer Risk Score

The Prostate Health Index combines p2PSA, free PSA, and total PSA into a cancer risk score that can help refine prostate biopsy decisions when PSA alone is uncertain.

The Prostate Health Index, or PHI, is a blood test that combines three forms of prostate-specific antigen—total PSA, free PSA, and proPSA, usually written...

Prostate-Specific Antigen (PSA) Test: Normal Range, High Levels, Screening, and Benign Causes

Learn what PSA levels mean, why benign prostate conditions can raise PSA, how age and risk affect screening, and when repeat testing, MRI, or biopsy may be considered.

A prostate-specific antigen, or PSA, test measures the concentration of PSA in blood. PSA is produced mainly by prostate tissue, so it is useful...

Prostatic Acid Phosphatase (PAP) Test: Prostate Cancer Marker, High Levels, and Historical Use

Learn what a prostatic acid phosphatase (PAP) test measures, why high levels were linked to advanced prostate cancer, why PSA replaced PAP, and how ACP3 is being studied again.

Prostatic acid phosphatase, or PAP, is an enzyme produced in high amounts by prostate tissue. Before prostate-specific antigen became widely used, serum PAP was...

PSA Density Test: Prostate Size, PSA Level, Cancer Risk, and Result Meaning

PSA density divides PSA by prostate volume to refine prostate cancer risk. Learn how PSAD is calculated, what 0.15 means, and how MRI changes biopsy decisions.

PSA density, often abbreviated PSAD, adjusts a blood PSA result for the size of the prostate. It is calculated by dividing PSA in ng/mL...

PSA Velocity Test: PSA Change Over Time and Prostate Cancer Risk

PSA velocity measures PSA change in ng/mL per year, but no velocity cutoff should trigger biopsy alone. Learn how trends are calculated, interpreted, and confirmed.

PSA velocity describes how quickly prostate-specific antigen changes over time, usually in ng/mL per year. A rising PSA can be clinically important, but PSA...

PSMA Test: Prostate-Specific Membrane Antigen, Imaging Marker, and Metastatic Disease

PSMA PET uses prostate-specific membrane antigen targeting to stage prostate cancer, detect biochemical recurrence, find metastases, and guide selected PSMA radioligand treatments.

A PSMA test usually refers to imaging that targets prostate-specific membrane antigen (PSMA), a cell-surface protein highly expressed by many prostate cancers. The most...

SelectMDx Test: Urine Gene Markers, Prostate Cancer Risk, and Result Meaning

SelectMDx measures HOXC6 and DLX1 urine gene markers after a prostate exam to estimate clinically significant prostate cancer risk and help guide MRI and biopsy decisions.

SelectMDx is a urine-based prostate cancer risk test that measures messenger RNA from the genes HOXC6 and DLX1 after a prostate-directed digital rectal examination....

AFP Test for Ovarian Germ Cell Tumors: High Levels, Tumor Marker Meaning, and Monitoring

Learn how AFP levels help diagnose and monitor ovarian germ cell tumors, what high results can mean, expected decline after treatment, and non-cancer causes.

An AFP test can help identify and monitor certain ovarian germ cell tumors, especially yolk sac tumors and mixed tumors that contain a yolk...

AMH Test for Ovarian Granulosa Cell Tumors: Tumor Activity, Monitoring, and Recurrence

Understand how AMH testing can track ovarian granulosa cell tumor activity, treatment response, and recurrence, plus what high or changing levels may mean.

An AMH test can be a useful blood marker for ovarian granulosa cell tumors because granulosa cells naturally produce anti-Müllerian hormone. In a patient...

Beta-hCG Test for Ovarian Germ Cell Tumors: High Levels, Tumor Marker Meaning, and Monitoring

Learn what high beta-hCG can mean in ovarian germ cell tumors, which tumor types raise hCG, how levels change with treatment, and causes of false positives.

A beta-hCG test can help diagnose and monitor ovarian germ cell tumors that produce human chorionic gonadotropin, especially choriocarcinoma, embryonal carcinoma, and mixed germ...

BRCA1 and BRCA2 Test for Ovarian Cancer: Hereditary Risk, DNA Repair, and Variant Meaning

Learn what BRCA1 and BRCA2 testing means in ovarian cancer, including hereditary risk, germline versus tumor results, VUS findings, DNA repair, and treatment relevance.

BRCA1 and BRCA2 testing can identify inherited cancer risk and tumor DNA-repair defects that matter in ovarian cancer care. These genes help repair dangerous...

BRIP1 Test for Ovarian Cancer: Hereditary Cancer Risk and Variant Meaning

Learn what a BRIP1 genetic test means for ovarian cancer risk, pathogenic variants, VUS results, family testing, screening limits, and risk-reducing surgery decisions.

A BRIP1 test looks for inherited variants in a DNA-repair gene that can raise the risk of ovarian, fallopian tube, and primary peritoneal cancer....